913184-73-3

Upstream product

• 905991-40-4 S-{8-[(2-{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy}ethyl)(methyl)amino]-3-mercapto-8-oxooctyl} [(tert-butoxycarbonyl)amino]ethanethioate 
• 108-24-7 acetic anhydride 
• 198990-14-6 tert-butyl (2-{4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy}ethyl)methylcarbamate 
• 905990-90-1 tert-butyl (2-{4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenoxy}ethyl)methylcarbamate 
• 198990-10-2 tert-butyl (2-(4-formylphenoxy)ethyl)(methyl)carbamate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 292615-81-7 N-(2-{4-[2,4-dioxo(1,3-thiazolidin-5-yl)methyl]phenoxy}ethyl)-N-methyl-6,8-disulfanyloctamide 
• 292615-76-0 N-(2-{4-[2,4-dioxo(1,3-thiazolidin-5-yl)methyl]phenoxy}ethyl)-5-(1,2-dithiolan-3-yl)-N-methylpentanamide 

Relevant academic research and scientific papers

Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARγ agonists

A series of novel derivatives of potent antioxidant vitamin, α-lipoic acid, and related analogues were designed, synthesized, and evaluated for their PPARγ agonist activities. Compounds 9a and the water soluble analogue 11e were found to be potent PPARγ agonists. Compound 9a appeared to have a significant role in improving insulin sensitivity and reducing triglyceride levels in fa/fa rats as well as inhibited proliferation of a variety of normal and neoplastic cultured human cell types. These novel compounds may prove efficacious not only in the treatment of Type 2 diabetes, but also atherosclerosis, prevention of vascular restenosis, and inflammatory skin diseases.